Keer HN - Search Results

1

Kwaan HC, Keer HN. Kwaan HC, et al. Among authors: keer hn. Semin Thromb Hemost. 1990 Jul;16(3):230-5. doi: 10.1055/s-2007-1002674. Semin Thromb Hemost. 1990. PMID: 2146746 Review. No abstract available.

2

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.

Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ. Keer HN, et al. Prostate. 1991;18(3):201-14. doi: 10.1002/pros.2990180303. Prostate. 1991. PMID: 1902292

3

Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.

Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Gaylis FD, et al. Among authors: keer hn. J Urol. 1989 Jul;142(1):193-8. doi: 10.1016/s0022-5347(17)38709-8. J Urol. 1989. PMID: 2659823

4

Components of the plasminogen-plasmin system in human tumor cell lines.

Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R. Kwaan HC, et al. Among authors: keer hn. Semin Thromb Hemost. 1991 Jul;17(3):175-82. doi: 10.1055/s-2007-1002607. Semin Thromb Hemost. 1991. PMID: 1839079 Review. No abstract available.

5

Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo.

Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Keer HN, et al. J Urol. 1990 Feb;143(2):381-5. doi: 10.1016/s0022-5347(17)39970-6. J Urol. 1990. PMID: 1688956

6

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D. Fang F, et al. Among authors: keer hn. Cancer Res. 2018 Feb 1;78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. Epub 2017 Dec 11. Cancer Res. 2018. PMID: 29229600 Free PMC article.

7

Methylomic Signatures of High Grade Serous Ovarian Cancer.

Cardenas H, Fang F, Jiang G, Perkins SM, Zhang C, Emerson RE, Hutchins G, Keer HN, Liu Y, Matei D, Nephew K. Cardenas H, et al. Among authors: keer hn. Epigenetics. 2021 Nov;16(11):1201-1216. doi: 10.1080/15592294.2020.1853402. Epub 2020 Dec 8. Epigenetics. 2021. PMID: 33289590 Free PMC article.

8

DNA profile of nephrogenic adenoma assessed by flow cytometry.

Gaylis FD, Keer HN, Bauer KD, Kozlowski JM, Grayhack JT. Gaylis FD, et al. Among authors: keer hn. Urology. 1993 Feb;41(2):160-1. doi: 10.1016/0090-4295(93)90172-7. Urology. 1993. PMID: 8497991

9

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. Oza AM, et al. Clin Cancer Res. 2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. Clin Cancer Res. 2020. PMID: 31831561 Free PMC article. Clinical Trial.

10

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.

Albany C, Fazal Z, Singh R, Bikorimana E, Adra N, Hanna NH, Einhorn LH, Perkins SM, Sandusky GE, Christensen BC, Keer H, Fang F, Nephew KP, Spinella MJ. Albany C, et al. Cancer Med. 2021 Jan;10(1):156-163. doi: 10.1002/cam4.3583. Epub 2020 Nov 1. Cancer Med. 2021. PMID: 33135391 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters